General Information of the Drug (ID: M6APDG02528)
Name
CPI-0610
Status
Phase 3
Structure
Formula
C20H16ClN3O2
InChI
1S/C20H16ClN3O2/c1-11-18-14-4-2-3-5-15(14)19(12-6-8-13(21)9-7-12)23-16(10-17(22)25)20(18)26-24-11/h2-9,16H,10H2,1H3,(H2,22,25)/t16-/m0/s1
InChIKey
GCWIQUVXWZWCLE-INIZCTEOSA-N
PubChem CID
57389999
TTD Drug ID
D01LVE
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Bromodomain-containing protein 4 (BRD4)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Bromodomain-containing protein 4 (BRD4) is a therapeutic target for CPI-0610. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CPI-0610 through regulating the expression of Bromodomain-containing protein 4 (BRD4). [1], [2]
References
Ref 1 mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature. 2018 Sep;561(7724):556-560. doi: 10.1038/s41586-018-0538-8. Epub 2018 Sep 19.
Ref 2 BET inhibitors in cancer therapeutics: a patent review. Expert Opin Ther Pat. 2016;26(4):505-22. doi: 10.1517/13543776.2016.1159299. Epub 2016 Mar 15.